TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29102648

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Radiation alone
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Systemic therapy alone
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Both radiation and systemic therapy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Systemic therapy with radiation
Number of subjects: 637
Study: 27323955

Group type: EXPERIMENTAL
Intervention: Autonomous condition (qualitatively trained researchers)
Number of subjects: 2552

Group type: COMPARATOR
Intervention: Assisted condition (OPO hospital development staff)
Number of subjects: 2552
Study: 24559003

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LcS) at a dose of 16 x 10(9) CFU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LcS) at a dose of 8 x 10(9) CFU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 22118417

Group type: EXPERIMENTAL
Intervention: Dexeryl (an emollient cream containing glycerol 15% and paraffin 10%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (its vehicle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexeryl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (previously treated group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 20616762

Group type: EXPERIMENTAL
Intervention: 6-dose group (reduced 5-component acellular pertussis vaccine combined with tetanus toxoid and reduced diphtheria toxoid)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 5-dose group (Tdap vaccine)
Number of subjects: 214
Study: 18356793

Group type: EXPERIMENTAL
Intervention: Electrostimulation of acupuncture points (LI4, ST36, HT7, LR3) for 20 minutes every hour for 12 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electrostimulation of acupuncture points
Number of subjects: 12
Study: 16022607

Group type: EXPERIMENTAL
Intervention: WHO technique
Number of subjects: 375

Group type: COMPARATOR
Intervention: Australian technique
Number of subjects: 375

Group type: COMPARATOR
Intervention: US technique
Number of subjects: 375
Study: 11827924

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 800

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 800

Group type: COMPARATOR
Intervention: AAD
Number of subjects: 800
Study: 9915320

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.050 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.100 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.200 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.300 mg/kg etomidate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.050 mg/kg etomidate (pretreatment)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (pretreatment)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.030 mg/kg etomidate (pretreatment)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg etomidate (pretreatment)
Number of subjects: 104
Study: 7751875

Group type: EXPERIMENTAL
Intervention: Single-agent bolus 5-FU
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Unmodulated infusion regimens
Number of subjects: 620

Group type: COMPARATOR
Intervention: 5-FU bolus therapy
Number of subjects: 620

Group type: COMPARATOR
Intervention: 5-FU bolus arms
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 620
Study: 2261951

Group type: EXPERIMENTAL
Intervention: Low-dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-dose ara-C (arm A)
Number of subjects: 63
Study: 6108606

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 7
Study: 30820319

Group type: EXPERIMENTAL
Intervention: FBH+ (Full Birth History with additional questions on pregnancy losses in the past 5 years)
Number of subjects: 68000

Group type: COMPARATOR
Intervention: FPH (Full Pregnancy History)
Number of subjects: 68000
Study: 28292270

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR)
Number of subjects: 14
Study: 26041848

Group type: EXPERIMENTAL
Intervention: FX006 (10 mg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: FX006 (40 mg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: FX006 (60 mg)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Immediate-release triamcinolone acetonide (40 mg)
Number of subjects: 228
Study: 23534896

Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fexofenadine 120 mg/day
Number of subjects: 0
Study: 20085851

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (26 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 19164608

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Lys supplement (beta-hydroxy-beta-methylbutyrate, L-arginine, and L-lysine)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control supplement (isonitrogenous)
Number of subjects: 77
Study: 17210383

Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus supervised exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus cilostazol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) plus supervised exercise plus cilostazol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Best medical therapy (BMT) alone
Number of subjects: 34
Study: 16338562

Group type: EXPERIMENTAL
Intervention: Cytochrome c peroxidase eyedrops (3 times a day for 1 week or until corneal reepithelialization was completed)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (standard postoperative therapy)
Number of subjects: 36
Study: 12389073

Group type: EXPERIMENTAL
Intervention: Grapefruit juice pretreatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral etoposide without grapefruit juice
Number of subjects: 6

Group type: COMPARATOR
Intervention: IV etoposide
Number of subjects: 6
Study: 9887419

Group type: EXPERIMENTAL
Intervention: Multifaceted bicycle helmet promotion program including classroom activities, parent education, helmet fitting and distribution, bicycle skills and safety event, and helmet requirement on school grounds.
Number of subjects: 880

Group type: COMPARATOR
Intervention: Control group with no helmet promotion activities.
Number of subjects: 880
Study: 8665721

Group type: EXPERIMENTAL
Intervention: Intranasal lysine aspirin (2000 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 2223348

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg‐1 i.v. before surgery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fentanyl 15 micrograms kg‐1 i.v. with corticotrophin releasing factor 100 micrograms i.v., growth hormone releasing hormone 100 micrograms i.v., and arginine vasopressin 10 units i.m.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms kg‐1 i.v. with releasing factors
Number of subjects: 2
Study: 543907

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: mezlocillin (slow injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ampicillin
Number of subjects: 50
Study: 30375661

Group type: EXPERIMENTAL
Intervention: Intensive‐intermittent music therapy (4x/week, off, 4x/week, off)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard spaced protocolised music therapy (2x/week)
Number of subjects: 24
Study: 28800385

Group type: EXPERIMENTAL
Intervention: New paediatric valaciclovir formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation (crushed and suspended tablets)
Number of subjects: 20
Study: 25727104

Group type: EXPERIMENTAL
Intervention: 0.015% ingenol mebutate gel (IMB) applied daily for three consecutive days
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5% 5-fluorouracil (5-FU) cream applied twice a day for 4 weeks
Number of subjects: 100
Study: 23859934

Group type: EXPERIMENTAL
Intervention: 8-week group motivational intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Biweekly newsletters by mail (Control)
Number of subjects: 69
Study: 20797441

Group type: EXPERIMENTAL
Intervention: Anticipatory mental imagery of a mildly fearful face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipatory mental imagery
Number of subjects: 0
Study: 20066950

Group type: EXPERIMENTAL
Intervention: Thoracic irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Innovative radiation technology
Number of subjects: 0
Study: 16765271

Group type: EXPERIMENTAL
Intervention: Treatment acceptability and effect among compliers
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Preference-based analysis
Number of subjects: 5
Study: 15636216

Group type: EXPERIMENTAL
Intervention: Topical 0.5% betaxolol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 114
Study: 11078488

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 353

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 353
Study: 7503497

Group type: EXPERIMENTAL
Intervention: Acyclovir, 400 mg twice daily for 70 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 1857729

Group type: EXPERIMENTAL
Intervention: Ventoline inhalation aerosol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orion salbutamol inhalation aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both salbutamol aerosols
Number of subjects: 0
Study: 6409917

Group type: EXPERIMENTAL
Intervention: Ipodate (3 g on days 1 and 5 of fasting)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: T3 (5 μg every 4 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ipodate plus T3
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting alone (Control group)
Number of subjects: 24
Study: 31419968

Group type: EXPERIMENTAL
Intervention: HIVRR plus Savings plus Financial Literacy (HIVRR + S + FL)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: HIVRR plus Savings plus Financial Literacy plus Vocational Skills Training and Mentorship (HIVRR + S + FL + V)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Only HIVRR (Control group)
Number of subjects: 990
Study: 28229457

Group type: EXPERIMENTAL
Intervention: Hydroxy progesterone injection
Number of subjects: 78

Group type: COMPARATOR
Intervention: Triamcinolone acetonide injection
Number of subjects: 78
Study: 27614989

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Syringe lidocaine
Number of subjects: 30
Study: 25683037

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) once daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Insulin detemir (IDet) once or twice daily
Number of subjects: 350
Study: 23194488

Group type: EXPERIMENTAL
Intervention: 10 mg/d rosuvastatin
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1462
Study: 20526152

Group type: EXPERIMENTAL
Intervention: Bilateral microdecompressive laminatomy (MDL)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Total laminectomy (TL)
Number of subjects: 71
Study: 18540935

Group type: EXPERIMENTAL
Intervention: Watching the video screen during the procedure
Number of subjects: 154

Group type: COMPARATOR
Intervention: Not watching the video screen during the procedure
Number of subjects: 154
Study: 15786754

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 mL/kg body weight/sec over 30 sec at an iodine concentration of 300 mgI/mL (Group 1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.06 mL/kg body weight/sec over 30 sec at an iodine concentration of 350 mgI/mL (Group 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 mL/kg body weight/sec over 25.7 sec at an iodine concentration of 350 mgI/mL (Group 3)
Number of subjects: 124
Study: 12424549

Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10349120

Group type: EXPERIMENTAL
Intervention: Saline group: 0.45% saline solution I.V., 1.5 cc/kg/min, 6 hours before and after the angiographic study
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dopa group: 0.45% saline solution I.V. plus dopamine 2 micrograms/kg/min, 30 minutes before the study until termination
Number of subjects: 75

Group type: COMPARATOR
Intervention: CONTROL GROUP: without interventions
Number of subjects: 75
Study: 7756151

Group type: EXPERIMENTAL
Intervention: 0.05‐0.1% tretinoin cream (Retin A, Ortho)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Purpose cream (vehicle control)
Number of subjects: 4
Study: 2192553

Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride (8 mg daily dosage limit, 40 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bismuth subsalicylate (4.9 g daily dosage limit)
Number of subjects: 0
Study: 794716

Group type: EXPERIMENTAL
Intervention: Naltrexone plus behavior therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Naltrexone alone
Number of subjects: 29
Study: 31822034

Group type: EXPERIMENTAL
Intervention: IPS-3 score of 0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS-3 score of 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS-3 score of 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS-3 score of 3
Number of subjects: 0
Study: 31540724

Group type: EXPERIMENTAL
Intervention: Porcine dermal patch augmentation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard medialized single-row repair
Number of subjects: 92
Study: 27335088

Group type: EXPERIMENTAL
Intervention: True moxibustion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 16
Study: 25493953

Group type: EXPERIMENTAL
Intervention: Social network score (SNS)
Number of subjects: 6972

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 6972

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 6972

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 6972
Study: 23070057

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day for 30 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (fertile women)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 12
Study: 21724007

Group type: EXPERIMENTAL
Intervention: Rigid laryngoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lighted stylet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 19635719

Group type: COMPARATOR
Intervention: rilonacept (IL1 Trap)
Number of subjects: 10
Study: 22404426

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study: 15997021

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Non-selective serotonin reuptake inhibitor antidepressants
Number of subjects: 1834
Study: 12885981

Group type: EXPERIMENTAL
Intervention: Oxygen (28%) before exercise
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oxygen (28%) after exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 52
Study: 9491504

Group type: EXPERIMENTAL
Intervention: MN rgp160 vaccine (200 μg doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MN rgp160 vaccine (800 μg fourth dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9098468

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) treatment
Number of subjects: 70
Study: 2759843

Group type: EXPERIMENTAL
Intervention: Group administered CBT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Individually administered CBT
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (wait list) control
Number of subjects: 22
Study: 931393

Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 50

Group type: COMPARATOR
Intervention: Camphor-in-oil placebo
Number of subjects: 50
Study: 12468785

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medically treated patients (historical control from NASCET)
Number of subjects: 42
Study: 29759063

Group type: EXPERIMENTAL
Intervention: Paracetamol and NSAIDs (specific dosages and duration not mentioned)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 4
Study: 26321037

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1180
Study: 25064723

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Ranibizumab or Bevacizumab (both treatments)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Baseline features
Number of subjects: 368
Study: 22774615

Group type: EXPERIMENTAL
Intervention: Shengjing Tablets
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vitamin E capsules (control group)
Number of subjects: 150
Study: 20669816

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate, 1040 ppm sodium fluoride dentifrice
Number of subjects: 79

Group type: COMPARATOR
Intervention: 8% arginine, calcium carbonate, 1450 ppm sodium monofluorophosphate dentifrice
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 79
Study: 18555575

Group type: EXPERIMENTAL
Intervention: Rebaudioside A (1000mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16234429

Group type: EXPERIMENTAL
Intervention: Monetary incentive (up to $0.50)
Number of subjects: 85671

Group type: EXPERIMENTAL
Intervention: Monetary incentive ($0.50 - $5.00)
Number of subjects: 85671
Study: 11893863

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Typical neuroleptics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both typical and atypical neuroleptics
Number of subjects: 20
Study: 10458052

Group type: EXPERIMENTAL
Intervention: Hierarchical multidimensional model with three or four first-order factors
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Hierarchical model with four first-order factors
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Hierarchical model with three first-order factors
Number of subjects: 507
Study: 8903629

Group type: EXPERIMENTAL
Intervention: Octreotide (1 mu g/kg body weight subcutaneously, twice a day at 0800 and 1800 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18
Study: 2633238

Group type: EXPERIMENTAL
Intervention: Pellet pancreatin (9 pellets/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tablet pancreatin (12 tablets/day)
Number of subjects: 30
Study: 323298

Group type: EXPERIMENTAL
Intervention: 50 mg triamterene plus 25 mg hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25 mg spironolactone plus 25 mg hydrochlorothiazide
Number of subjects: 0
Study: 31923177

Group type: EXPERIMENTAL
Intervention: Ivermectin plus phenobarbital
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phenobarbital alone
Number of subjects: 90
Study: 30464234

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n = 14), three 50‐min sessions weekly from 16 weeks gestation to delivery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n = 14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-exercise control group (n = 22)
Number of subjects: 36
Study: 26422394

Group type: EXPERIMENTAL
Intervention: Bivalved cast immobilization
Number of subjects: 202

Group type: COMPARATOR
Intervention: Circumferential cast immobilization
Number of subjects: 202
Study: 25920599

Group type: EXPERIMENTAL
Intervention: PDRN injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline injection (placebo)
Number of subjects: 40
Study: 24019047

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) - one Fleet enema on the morning of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-mechanical bowel preparation (non-MBP) - no enema before surgery
Number of subjects: 40
Study: 21474338

Group type: EXPERIMENTAL
Intervention: Supraclavicular approach for subclavian vein (n = 65)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Infraclavicular approach for subclavian vein (n = 65)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Internal jugular vein approach (n = 65)
Number of subjects: 195
Study: 19663521

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once daily for 1 year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily for 1 year
Number of subjects: 72
Study: 16788808

Group type: EXPERIMENTAL
Intervention: Early enteral immunonutrition (iEN)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 326
Study: 12684363

Group type: EXPERIMENTAL
Intervention: Internet plus behavioral e‐counseling program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Basic Internet program
Number of subjects: 92
Study: 10980875

Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa receptor blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8623742

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 21
Study: 1446142

Group type: EXPERIMENTAL
Intervention: GR32191, 40 mg four times daily for 3 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9